Raymond James Financial
RIGL icon

Raymond James Financial’s Rigel Pharmaceuticals RIGL Stock Holding History

Raymond James Financial’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Sell
38,133
-5,622
-13% -$189K ﹤0.01% 3827
2025
Q4 		$1.87M Buy
43,755
+236
+0.5% +$8.9K ﹤0.01% 3324
2025
Q3 		$1.23M Buy
43,519
+43,419
+43,419% +$1.3M ﹤0.01% 3545
2025
Q2 		$1.87K Buy
+100
New +$1.9K ﹤0.01% 6432

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's RIGL Position: Q1 2026 in Review

Raymond James Financial reduced its Rigel Pharmaceuticals (RIGL) stake by 13% in Q1 2026, selling an estimated $189K and leaving 38,133 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3827.

Raymond James Financial first reported a position in RIGL in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.87M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Raymond James Financial held 38,133 shares of Rigel Pharmaceuticals worth $1.03M as of Q1 2026.
  • Raymond James Financial sold 5,622 Rigel Pharmaceuticals shares in Q1 2026, an estimated $189K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3827 holding.
  • Raymond James Financial first reported a position in Rigel Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Rigel Pharmaceuticals position peaked at $1.87M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.